登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>VEGF165 >VE5-H8210

Biotinylated Human VEGF165 Protein, epitope tag free, ultra sensitivity, primary amine labeling

热销产品推荐:

利用生物素-链霉亲和素系统的高特异性和高灵敏度的结合特性,可将生物素化蛋白与链霉亲和素相关产品联合应用于各类实验,与非生物素体系相比,检测速度更快、结合能力更强、非特异背景更低。

分子别名(Synonym)

RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF

表达区间及表达系统(Source)

Biotinylated Human VEGF165, epitope tag free, primary amine labeling (VE5-H8210) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4 ).

Predicted N-terminus: Ala 27

Request for sequence

蛋白结构(Molecular Characterization)

VEGF165 Structure

This protein carries no "tag".

The protein has a calculated MW of 19.2 kDa. The protein migrates as 23-25 kDa under reducing (R) condition, and 40-50 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

标记(Labeling)

The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.

蛋白标记度(Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 24 months in lyophilized state;
  2. -70°C for 24 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

VEGF165 SDS-PAGE

Biotinylated Human VEGF165, epitope tag free, primary amine labeling on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

VEGF165 ELISA

Immobilized human VEGFR1/R2, Fc Tag at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, epitope tag free, primary amine labeling (Cat. No. VE5-H8210) with a linear range of 0.4-3 ng/mL (QC tested).

Protocol

VEGF165 BATCH ELISA
VEGF165 ELISA

Immobilized Anti-VEGF MAb,Human IgG1 (Avastin) at 5 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, epitope tag free, primary amine labeling (Cat. No. VE5-H8210) with a linear range of 0.2-4 ng/mL (Routinely tested).

Protocol

VEGF165 ELISA

Immobilized Human Neuropilin-1, His Tag (Cat. No. NR1-H5228) at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, epitope tag free, primary amine labeling (Cat. No. VE5-H8210) with a linear range of 0.031-2 μg/mL (Routinely tested).

Protocol

 

背景(Background)

VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.

文献引用(Citations)

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
VEGF165靶点信息
英文全称:Vascular endothelial growth factor A
中文全称:血管内皮生长因子A
种类:Homo sapiens
上市药物数量:39详情
临床药物数量:65详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定